Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatoid Arthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatoid Arthritis
    Risk of TB Higher for Patients Taking Infliximab, Adalimumab, Than Etanercept - (DGNews)
    Golimumab Effective in Patients With RA Who Have Poor Response to Other Drugs - (DGNews)
    TopAbstracts in Rheumatoid Arthritis 06/25/2009 - (DGNews)
    Initial Therapy With Adalimumab Plus Methotrexate Leads to Better Outcomes Over 5 Years in Patients With Early Rheumatoid Arthritis: Presented at EULAR - (DGDispatch)
    Abatacept Plus Methotrexate Safe, Effective for Up to 5 Years in Patients With Rheumatoid Arthritis: Presented at EULAR - (DGDispatch)

    News archive

     Recent webcasts/CME - Rheumatoid Arthritis
    • Benefits of Early, Aggressive, and Appropriate Intervention in Rheumatoid Arthritis
    • Safety of Novel Immunomodulatory Therapies
      Rheumatoid Arthritis: The Heart of the Matter Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis
      New Recommendations for Disease-Modifying Antirheumatic Drugs and Emerging Options for the Treatment of Rheumatoid Arthritis
      Failing a TNF Inhibitor: What About Switching?

      Webcasts/CME archive

       Recent cases - Rheumatoid Arthritis
        Patient with Hepatitis B and Rheumatoid Arthritis
        Autologous Chondrocyte Implantation for Rheumatoid Arthritis of the Knee: A Case Report
        Complete Heart Block and Severe Aortic Stenosis in a Patient with Rheumatoid Arthtritis: A Case Report
        Limited Wegener's Granulomatosis Presenting as Lung Nodules in a Patient with Rheumatoid Arthritis: A Case Report
        Aseptic Meningitis in a Patient Taking Etanercept for Rheumatoid Arthritis: A Case Report

        Cases archive
          




        my personal edition > rheumatoid arthritis > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Etanercept Reduces Number of Proinflammatory Cytokine-Secreting Peripheral Blood Mononuclear Cells in Patients with Rheumatoid Arthritis

        A DGReview of :"Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis"
        Rheumatology

        03/29/2004
        By Emma Hitt, PhD


        Long-term treatment with etanercept in patients with rheumatoid arthritis (RA) appears to reduce the numbers of proinflammatory cytokine-secreting peripheral blood mononuclear cells (PBMC), while the number of IL-10-secreting cells is unaffected, perhaps accounting for the long-term systemic effects.

        A significant proportion of patients fails to respond to etanercept. Both RA and etanercept influence cytokine levels; thus, the immunomodulatory effects of etanercept in vivo are of interest for predicting response and prognosis.

        H. Schotte, MD, with the Universitatsklinikum Munster, in Germany, and colleagues determined the influence of etanercept treatment on the number of PBMC secreting immunoregulatory key cytokines and the correlation of these cell counts with treatment response in 19 patients with RA treated with etanercept monotherapy.

        Frequencies of PBMC secreting cytokines were determined by ELISPOT analysis before and after 9 months of therapy and compared with values for healthy controls. The clinical outcome was assessed as defined by American College of Rheumatology (ACR) criteria.

        Fifteen patients fulfilled ACR20, 7 fulfilled ACR50, and 2 fulfilled ACR70 criteria. Initially elevated levels of tumour necrosis factor-alpha- and interleukin (IL)-1beta-secreting PBMC were reduced compared to those of controls. In addition, normal or low numbers of IL-6- and interferon-gamma (IFN-gamma)-secreting PBMC were reduced below those of control levels.

        The number of IL-10-secreting PBMC did not differ from that of healthy controls and did not change significantly over time. The pretreatment IFN-gamma:IL-10 ratio correlated to reduction in the tender and swollen joint counts.

        "Our results provide evidence that long-term treatment with etanercept substantially down-regulates the activated systemic proinflammatory cytokine cascade in RA," Dr. Schotte and colleagues conclude. "The ratio of IFN-gamma:IL-10 secreting PBMC may serve as a prognostic parameter for the clinical response to etanercept treatment," they suggest.

        Rheumatology (Oxford) 2004 Mar 16;[Epub ahead of print]. "Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send